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A B S T R A C T
Purpose: We investigated the inﬂuence of the CYP2C9 polymorphism on the lipid proﬁle, insulin
resistance, and subclinical atherosclerosis in young epileptic patients.
Methods: We performed a cross-sectional study to evaluate the association between CYP2C9
polymorphism and lipid proﬁle, glucose homeostasis, and subclinical atherosclerosis in young epileptic
patients via the ankle brachial index.
Results: The frequencies of CYP2C9*1 (CYP2C9 wild type gene) and CYP2C9*3 (CYP2C9 polymorphism
gene) were 75% and 25%, respectively. The mean serum total triglyceride and LDL levels were
signiﬁcantly higher in the wild type gene subjects than in the CYP 2C9 polymorphism gene subjects. Also,
the CYP 2C9 polymorphism had marginally signiﬁcant lower mean serum HDL levels than the wild type
gene subjects. No patients with CYP 2C9 polymorphism gene had elevated fasting blood sugar, and
insulin resistance was found in only 10 of the 75 subjects. The mean ABI was statistically signiﬁcantly
lower in the wild type subjects than in the CYP2C9 polymorphism gene subjects.
Conclusion: Our study indicates that young epileptic patients with the CYP2C9 polymorphism gene have
a low risk of subclinical atherosclerosis.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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The inﬂuence of antiepileptic drug (AED) therapy on the
development of atherosclerosis has been the subject of controver-
sy, although recent evidence indicates that prolonged antiepileptic
treatment might modify some vascular risk factors.1 The existing
data on the effect of phenytoin (PHT) on atherosclerosis are
contradictory. There is some evidence that PHT may contribute to
protecting some patients form atherosclerosis by increasing the
concentration of high density lipoproteinemia cholesterol2 and
atherogenic cholesterol fractions.3 However, a recent study from
Thailand showed PHT inhibited the secretion of insulin and
decreased the response of plasma insulin to glucose, a condition
known as insulin resistance,4 which can induce atherosclerosis.
However, both apparent positive and negative effects of PHT show
individual differences, and the factors that cause such individual
differences remain unclear. An experimental study examining the* Corresponding author. Tel.: +66 74451452.
E-mail address: pkanitpo@medicine.psu.ac.th (K. Phabphal).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.10.013results of PHT treatment on atherosclerosis susceptibility and lipid
proﬁle in mice found that PHT treatment had a protective effect,
and that the atherosclerosis prevention was not concomitant with
a consistent increase in HDL or any other protective change in the
lipid proﬁle.5
To date, atherosclerosis remains a complex multifactorial
disorder that is thought to result from an interaction between
the genetic make-up of an individual and various environmental
factors. Cytochrome P450 is partly responsible for the biosyn-
thesis of endogenous vasoregulators.6 In addition, CYP2C9 also
generates signiﬁcant amounts of oxygen-derived free radicals.7
The other mechanism of PHT-induced atherosclerosis is via
insulin resistance and increased total cholesterol, total triglyc-
eride, and LDL-C. Currently, no studies are available on the
impact of CYP2C9 mutation alleles on metabolic abnormalities
and subclinical atherosclerosis of young epileptic patients who
are taking PHT as monotherapy. We therefore investigated the
inﬂuence of the CYP2C9*2 and CYP2C9*3 variants on the lipid
proﬁle, insulin resistance, and subclinical atherosclerosis in
young epileptic patients with who were receiving PHT mono-
therapy in Thailand.vier Ltd. All rights reserved.
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This was a single-center, university hospital-based, cross-
sectional study conducted from October 2010 to May 2012. We
recruited ambulatory young Thai adults with epilepsy who had
been treated with phenytoin monotherapy for at least 2 years. All
of our patients had focal onset epilepsy. The inclusion criteria
were: a Thai national with epilepsy; age 20–40 years, stable dosage
of PHT (during the previous 6 months), no chronic medical illness
other than epilepsy, taking no medication except an antiepileptic,
with an active daily life (could perform activities of daily living
without assistance), not drinking alcohol or smoking, and no family
history of diabetes. Patients who had previously taken an AED but
had stopped at least 3 years prior to the beginning of this study
were allowed. Because at our institution we routinely give folic
acid to epileptic patients, patients taking a stable dosage of folic
acid (5 mg/d) for at least 1 year were also accepted. Exclusion
criteria were: pregnancy; having a signiﬁcant medical disorder
other than epilepsy known to affect lipid metabolism or glucose
homeostasis, alcohol drinking, and/or smoking in the past 5 years.
The Ethics Review Committee of the Faculty of Medicine, Prince
of Songkla University, approved the study and informed consent
was sought and obtained from all patients.
Each subject completed a questionnaire covering basic demo-
graphics such as sex and age, and medical details such as age at
onset of epilepsy, duration of treatment, and current and past
medication usage. Weight and height were also measured and the
body mass index was calculated [body weight (kg)/height2 (m)].
1.2. Laboratory procedures
Baseline control data were obtained in the morning after a 10-h
overnight fasting period. The serum glucose level was determined by
enzymatic hexokinase (Modular P800; Roche Diagnostics, Germany)
and the serum insulin level by electrochemiluminescence immuno-
assay [ECLIA] (Modular E170; Roche Diagnostics, Germany). The
sensitivity of the assay was 0.200 mU/L, and the coefﬁcients of
variation were 1.38% and 0.87% for intra-assay, and 4.20% and 3.97%
for interassay, respectively (intra-assay: n = 20, mean = 24.06 mU/L,
SD  0.33 and mean = 80.05 mU/L, SD  0.70; interassay: n = 20,
mean = 22.70 mU/L, SD  0.95 and mean = 79.26 mU/L, SD  3.15).
Using the fasting glucose and insulin levels, we calculated the
homeostasis model assessment (HOMA) index for each patient,
using the following equation:
HOMA-index ¼ fasting glucose ðmmol=L  fasting insulin ðmIU=LÞÞ
22:5
HOMA-IR values have been shown to correlate well with values
obtained using the ‘‘gold standard’’ clamp technique.8 Patients
above the threshold of 1.73 were classiﬁed as having insulin
resistance.9 Trough serum levels for AEDs were examined.
1.3. Diagnosis of metabolic syndrome
The criteria of metabolic syndrome require at least three of the
following conditions: (1) obesity, (2) hypertriglyceridemia (at
least 150 mg/dL), low high-density lipoprotein (HDL) cholesterol
(<40 mg/dL in men and <50 mg/dL in woman), and (3)
hypertension (at least 130/85 mm Hg, and (4) impaired glucose
tolerance, according to the Adult Treatment Panel III.10
1.4. ABI measurement
Standardized ABI measurements were performed according
to the AHA recommendations for the evaluation of peripheralartery disease (PAD) by a physician with experience in ABI
recording. ABI was measured using a handheld 8 MHz handheld
Doppler device (MiniDop ES-100VX, Hadeco Inc, Japan). Systolic
pressure was measured both in the dorsalis pedis and in the
posterior tibial artery. The higher of these pressures was divided
by the higher of the two brachial systolic pressures to calculate
the ABI. An ABI  0.90 in either leg was considered as evidence of
asymptomatic PAD, and an ABI >0.90 was considered as
normal.11
1.5. CYP2C9 genotyping
Genomic DNA was isolated from leukocyte nucleids using a
QIAamp DNA Mini Kit (QIAGEN). Realtime HRM PCR (realtime
polymerase chain reaction high resolution melting) was performed
in a strip tube with a reaction volume of 20 mL, containing 2 mL of
SsoFast Evagreen Supermix ‘‘BioRad’’ (ready to use reactionmix),
0.15 mM of the forward and reverse primers for CYP2C9*2 and
CYP2C9*3, and 100 ng/mL of genomic DNA. The sequences of
forward and reverse primers used were respectively
50TACAAATACAATGAAAATATCATG30 and 50 CTAACAACCAGA
CTCATAATG 30 for CYP2C9*2 (Arg144Cys) genotype and 50
AATAATAATATGCACGAGGTCCAGAGGTAC 30 and 50 GATACTAT-
GAATTTGGGACTT C 30 for CYP2C9*3 (Ile359Leu) genotype (these
primers were described by Ramasamy et al.12 and synthesized by
BioDesign Co., Ltd.).
Realtime PCR ampliﬁcation to detect CYP2C9*2 and/or
CYP2C9*3 was performed using CFX 96 Connect Realtime-PCR
(Bio-Rad Laboratories USA) with an initial denaturation at
95.0 8C for 3 min, followed by 40 cycles of denaturation at
95.0 8C for 10 s, annealing at 59.0 8C for 15 s, and ﬁnal extension
at 95.0 8C for 10 s. A melt curve was plotted from 73.0 8C to
85.0 8C, with an increment of 0.2 8C every 10 s. The analysis of
melt curves used a high-resolution melt curve (HRM) method on
Precision Melt Analysis software version 1.1 (Bio-Rad Laborato-
ries USA). Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) used the same primer sets as the
Realtime PCR. PCR was performed at a reaction volume of 20 mL,
consisting of 2 mL of Top Taq Master Mix ready-to-use reaction
mix (QIAGEN), 0.2 mM each of the forward and reverse primers
for CYP2C9*2 and CYP2C9*3, and 100 ng/ml of genomic DNA. PCR
was performed in a S1000-PCR thermal cycler (Bio-Rad
Laboratories USA) with an initial denaturation at 94.0 8C for
4 min, followed by 40 cycles of denaturation at 95.0 8C for 30 s,
annealing at 56.0 8C for 30 s, extension at 72.0 8C for 45 s and
ﬁnal extension at 72.0 8C for 10 min. An 8 mL alliquot from each
PCR product was digested with 5 U of restriction enzymes AvaII
(Promega) and 5 U of Kpn I (Takara), for CYP2C9*2 and
CYP2C9*3, respectively. Incubation was done at 37 8C overnight.
Detection of the digested product was performed with 12%
polyacrylamide gel electrophoresis, using 120 V for 2 h 30 min.
The PCR-RFLP results were randomly selected to be conﬁrmed by
direct nucleotide sequencing on an ABI 3130 Genetic Analyzer
with 3130 Collection Software.
2. Statistical analysis
The characteristics of the study patients were described in
terms of mean and standard deviation for continuous variables,
and number and percentage for categorical variables. Compar-
isons of continuous variables between the two subgroups of
subjects were made using a two-tailed t-test. Correlations
between serum level of PHT and fasting glucose, fasting insulin,
and lipid proﬁle parameters in the CYP2C9 gene group were
explored using Pearson product moment correlation coefﬁcient.
Table 1
Demographic and other data of study patients.
Variable Wild type gene
(n = 56)
CYP2C9 polymorphism (n = 19)
Average age (years; range) 29.93 (20–40) 30.42 (20–40)
Sex (male:female) 39:17 12:7
Average duration of AED use (years; range) 3.85 (2–5.7) 3.47 (2–5.5)
Type of seizure (n)
Focal onset
Simple with or without generalized seizure complex 40 14
Partial with or without generalized seizure 16 5
Etiology
Unknown 51 17
Structural
Head injury 3 1
Central nervous system infection 2 1
Through serum PHT level (mean; range) 16 (10–23) 19 (17–23)
Seizure control
Seizure freea 42 14
Well-controlledb 14 5
a Deﬁned as seizure free for >24 months under AED therapy.
b Deﬁned as seizure free for >12 months under AED therapy.
A
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(Stata Statistical Software: Level 7.0 College Station, TX, USA).
3. Results
For the present study, we recruited 75 young epileptic
patients who were taking PHT monotherapy, whose demograph-
ic characteristics and basic laboratory data are shown in Table 1.
Ninety one percent had a diagnosis of unknown epilepsy, 5% of
head injury, and 4% of central nervous system infection (Table 1).
A majority (75%) were seizure free for more than 24 months.
There were 51 males and 24 females, with a mean age (SD) of
30.1  5.6years (range: 20–40 years). The mean duration of
treatment (SD) with antiepileptic drug use for the overall group
at the time of the study was 3.8  0.99 years (range: 2–5.7 years).
The mean (SD) serum level of PHT was 16.8  3.2 (range 10–
23) mg/L. About 24% (18 out of 75) were found to be CYP2C9*3
heterozygous carriers (wt/mt), and 1.3% (1 out of 75) were
CYP2C9*3 homozygous (mt/mt), which is characterized by poor
PHT metabolism. No CYP2C9*2 polymorphism were identiﬁed.Table 2
Vascular risk factors and ABI in study patients.
Characteristic CYP 2C9 genotype 
Wild type (n = 56) 
Mean  SD 95% CI 
Average age, SD (years) 29.2  5.3 28.5–31
Sex 
Male (n) 39 
Female (n) 17 
Duration of treatment (years) 3.85  0.98 3.59–4.1
Serum phenytoin level (mg/L) 15.9  3.1 15–17
BMI (kg/m2) 24.4  2.5 23.7–25
Fasting blood glucose (mmol/L) 93.9  7.7 91.8–95
Systolic blood pressure (mm Hg) 131.4  7.8 129.3–13
Diastolic blood pressure (mm Hg) 81.0  6.8 79.2–82
Fasting blood insulin (mIU/L) 6.4  1.1 6.1–6.7
Total triglycerides (mg/dL) 147.9  35.5 138.4–15
Total cholesterol (mg/dL) 209.8  37.8 199.7–22
LDL cholesterol (mg/dL) 134.5  26.1 127.5–14
HDL cholesterol (mg/dL) 65.4  5.1 64.1–66
HOMA 1.48  0.37 1.40–1.5
BI
Left leg 0.94  0.08 0.92–0.9
Right leg 0.92  0.08 0.89–0.9
BMI, body mass index; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprWe then classiﬁed the patients into 2 groups: (1) the CYP2C9
polymorphism gene group, which included patients who had
homozygous or heterozygous CYP2C9*3; and (2) the wild type
gene of CYP2C9 group, which included those identiﬁed as wild type
CYP2C9*1. The CYP2C9 polymorphism group included 19 mem-
bers, 12 males and 7 females, with a mean (SD) age of 30.4 (5.6)
years (range 20–40 years). There were no signiﬁcant differences
between the CYP2C9 polymorphism group and the wild type gene
group in sex or age. The mean (SD) duration of treatment was not
signiﬁcantly different between groups; those in the CYP2C9
polymorphism group had been treated for an average of 3.47  1.0
years (range: 2–5.5 years), while the wild type gene group had been
treated for an average of 3.85  0.98 years (range: 2–5.7 years)
(p = 0.15). The other basic demographics of both groups are shown in
Table 1; there were no signiﬁcant differences in any variables
between the groups. However, the CYP2C9 polymorphism group had
higher serum levels of phenytoin, compared with the wild type gene
group (p < 0.01).
The individual vascular risk factors in both groups are
summarized in Table 2. The mean (SD) serum total cholesterolp value
CYP2C9 polymorphism (n = 19)
Mean  SD 95% CI
.3 30.4  5.6 27.2–33.6 0.74
0.92
12
7
1 3.47  1.0 2.99–3.96 0.15
 19  1.9 18–20 <0.01
.1 24.5  2.9 23.1–26 0.84
.9 97.8  5.8 95.0–100.6 0.04
3.5 132.5  6.3 129.4–135.5 0.58
.9 82.7  5.7 80.0–85.5 0.33
 7.2  2.2 6.1–8.2 0.04
7.4 129.1  16.9 121.0–137.3 0.03
0.0 186.9  40.3 167.5–206.4 0.03
1.5 116.8  35.3 99.8–133.9 0.02
.8 60.9  15.1 53.6–68.1 0.05
5 1.63  0.59 1.35–1.92 0.12
6 0.98  0.06 0.95–1.00 0.03
4 0.96  0.04 0.94–0.98 0.04
otein cholesterol; HOMA, homeostasis model assessment. ABI, ankle brachial index.
Table 3
Prevalence of individual components of vascular risk factors by sex in patients with
the CYP 2C9 genotype polymorphism.
Variable Wild type
(n = 56)
CYP 2C9
polymorphism
(n = 19)
Glucose homeostasis
Fasting blood sugar (110) 2 0
Abnormal HOMA (1.73) 11 10
Lipid proﬁle
Total cholesterol (200 mg/dL) 35 8
Total triglyceride (150 mg/dL) 31 4
LDL (130 mg/dL) 16 4
HDL (<40 mg/dL in men, <50 mg/dL)) 0 1
Overweight (BMI > 23) 39 12
BMI, body mass index; LDL, low-density lipoprotein cholesterol; HDL, high-density
lipoprotein cholesterol; HOMA, homeostasis model assessment.
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than in the CYP 2C9 polymorphism group (8  37.8 vs. 186.9  40.3).
The mean (SD) serum total triglyceride and LDL levels were also
signiﬁcantly higher in the wild type gene group than in the CYP 2C9
polymorphism group (147.9  35.5 vs. 129.1  16.9, p = 0.03 and
134.5  26.1 vs. 116.8  35.3, p = 0.02 respectively). The wild type
group had marginally signiﬁcantly (p = 0.05) higher mean (SD)
serum HDL levels than the CYP2C9 polymorphism group (65.4  5.1
vs. 60.9  15.1). Table 3 shows the prevalence of individual risk
factors of atherosclerosis by CYP genotype. Overall, elevated fasting
glucose (>110 mg/dL) was identiﬁed in 2 (2.6%) patients, and insulin
resistance (HOMA  1.73) in 21 (28%) patients. High total concentra-
tions of cholesterol (200 mg/dL) were noted in 43 (57.3%) patients.
Thirty-ﬁve patients (46.7%) had high serum triglyceride concentra-
tions (150 mg/dL), 20 (26.7% had high LDL-C concentration
(130 mg/dL), and 1 (1.3% had low HDL concentrations (<40 mg/
dL in men, < 50 mg/dL (<40 mg/dL in men, <50 mg/dL)). In patients
with CYP2C9 polymorphism, no patient had elevated fasting blood
sugar (>110 mg/dL). Insulin resistance (HOMA  1.73) was found in
10 of the 19 patients Also, high total concentrations of cholesterol
(200 mg/dL) were noted in 8 of the 19 patients, high serum
triglyceride concentrations (150 mg/dL) in 4 of 19 patients, high
LDL-C concentrations (130 mg/dL) in 4 of 19 patients, and low HDL
levels in 1 of 19 patients (Table 3). The mean systolic and diastolic
blood pressure levels were not statistically signiﬁcantly different
between the groups (p = 0.58 and p = 0.33 respectively).
The mean (SD) ABI was statistically signiﬁcantly lower in the
wild type gene group than in the CYP 2C9 polymorphism group in
both legs (left leg 0.94  0.08 vs. 0.98  0.06, p = 0.03; right leg
0.92  0.08 vs. 0.96  0.04, p = 0.04). Overall, the results of the study
showed that ABI was not related to age, gender, serum PHT level, BMI
and duration of AED therapy. Also, the fasting blood level was not
associated with serum PHT.
4. Discussion
To our knowledge, this is the ﬁrst study to investigate the
effect of CYP2C9 polymorphism on insulin resistance, lipid
proﬁle, and subclinical atherosclerosis in epileptic patients
taking PHT. The study found that epileptic patients who had the
CYP2C9 polymorphism had lower total triglyceride, total
cholesterol, LDL cholesterol, and HDL cholesterol levels than
epileptic patients who had the wild type gene. However, the
epileptic patients who had the CYP2C9 polymorphism had lower
fasting blood sugar levels than those with the wild type gene,
although no insulin resistance. In addition, patients with the
CYP2C9 polymorphism also had statistically signiﬁcantly higher
ankle brachial indexes than patients with the wild type gene.The CYP P450 superfamily represents one group of important
Phase I drug metabolizing enzymes that oxidize a number of
endogenous compounds and xenobiotics, including PHT.13 The
most common polymorphisms that have signiﬁcant clinical
importance are CYP2C9*2 and CYP2C9*3; CYP2C9*1 refers to the
wild-type gene. The identiﬁed mutant alleles of CYP2C9, CYP2C9*2
and CYP2C9*3 have 70% and 3–5% enzyme activity compared with
the wide-type gene, CYP2C9*1.13 Approximately 40% of the white
and 5% of the Asian or black populations are heterozygous for
either CYP2C9*2 or CYP2C9*3 and demonstrate a signiﬁcantly
decreased CYP2C9 activity compared with those having CYP2C9*1/
*1.13 Kuanprasert et al. conducted a study on valvular heart
disease in Northern Thailand and found that 95% of 242 patients
under investigation had CYP2C9*1/*1; CYP2C9*1/*3 was found in
the remaining 5%. Neither the mutant CYP2C9*2 allele nor the
individual homozygote for CYP2C9*3 were found in this study.14
Surprisingly, our study found that the CYP2C9 polymorphism had a
prevalence of 25%. About 24% (18 out of 75) of epileptic patients
were found to be CYP2C9*3 heterozygous carriers (wt/mt) and 1.3%
(1 out of 75) were CYP2C9*3 homozygous (mt/mt), which is
characterized by the phenotype with poor PHT metabolism. No
homozygous or heterozygous CYP2C9*2 were found. Compared
with other Asian countries, there was a signiﬁcantly high
frequency of CYP2C9 polymorphism in our study.
Metabolic abnormalities such as increased levels of total
cholesterol, total triglyceride and LDL-cholesterol, low levels of
HDL cholesterol and high fasting blood sugar, are independent
risk factors of atherosclerosis.15 Previous reports have suggested
that vascular risk factors are more prevalent in chronic
epilepsy.16–18 There are a limited number of studies on the
effect of PHT on lipid proﬁles in adult epileptic patients. Nikolaos
et al., found that adult epileptic patients with CYP P450 enzyme-
inducing AED had increased serum levels of total cholesterol,
HDL cholesterol, LDL cholesterol and total triglycerides.16 In a
recent study, we controlled the confounding factors which can
effect the lipid proﬁle, and found that PHT patients had an
increased mean value of serum total cholesterol, total triglycer-
ide and serum LDL cholesterol as compared to patients with
epilepsy taking valproate and those who had not previously
taken any AEDs.4 The mechanism responsible for the change in
lipid proﬁle amongst patients taking PHT may be due to the
effect of CYP 450 induction.19 There is a correlation between the
serum lipid and hepatic microsomal enzyme activity and
CYP450 content in liver biopsy specimens.20 To date, however,
no study has focused on the effect of the CYP2C9 polymorphism
on serum lipid proﬁles. In our study, we found that epileptics
who had the CYP2C9*3 polymorphism had statistically signiﬁ-
cant lower total cholesterol, total triglyceride HDL cholesterol,
and LDL cholesterol than epileptic patients who had the wild
type of CYP2C9. Interestingly, this result was not associated with
the serum PHT levels, suggesting the effect of PHT on the lipid
proﬁle does not depend on the PHT itself but is an indirect effect
on the CYP P450 enzyme system, which is involved extensively
in the synthesis and metabolism of cholesterol.
High serum blood glucose and insulin resistance are the
important risk factors of atherosclerosis. The effect of PHT on
glucose homeostasis in patients with epilepsy is limited. To date
we know of only three studies that have been conducted in this
area. Two studies examined glucose tolerance and insulin
secretion in epileptic patients who were on long-term PHT
therapy, and found no evidence of insulin resistance.21,22 These
studies had numerous limitations, however, notably a lack of
BMI comparison between the groups, serum levels of PHT and
insulin resistance, and small sample sizes. Our previous study
controlled for all of these confounding factors and found that
insulin resistance was statistically signiﬁcantly higher in
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taking valproate or epileptic patients who were not taking
AEDs.4 The mechanism of PHT-induced insulin resistance has not
been well established. Some evidence has been found showing
an association between serum levels of PHT and delays in
reaching peak glucose concentrations.21 In this current study, we
analyzed the association of serum levels of PHT and fasting blood
sugar, but found no correlation between these levels. We
compared the CYP2C9 polymorphism with the wild type gene
with fasting blood sugar, and found that the CYP2C9 polymor-
phism group had statistically signiﬁcant higher levels than the
wild type gene (p = 0.04). Also, patients who had a CYP2C9
polymorphism had higher serum insulin levels than patients
with the wild type gene (p = 0.04), but no statistically signiﬁcant
levels of insulin resistance (p = 0.12). The mechanism of
association between CYP2C9 polymorphism and serum insulin
level needs to be explored further.
Concerning the association between lipid abnormality, insulin
resistance and atherosclerosis, we aim to explore the effects of
CYP2C9 polymorphism on subclinical atherosclerosis in epileptic
patients taking PHT, as measured by the ankle brachial index. The
ankle brachial index (ABI) and carotid intima-media thickness are
two well-studied markers of atherosclerosis that are useful in risk
stratiﬁcation.23 Our study found that wild type gene patients
taking PHT as monotherapy had a statistically signiﬁcant lower ABI
at the left and right leg than those who had the CYP2C9
polymorphism (p = 0.03 and 0.04 respectively). A low ABI
(0.90) at rest indicates a high risk of peripheral vascular disease
and provides signiﬁcant evaluative and prognostic information on
cardiovascular risk. In our study, 34.7% of patients taking PHT had a
low ABI at one or both sites. Also, we separated the patients into
CYP2C9 polymorphism and wild type gene, and found low ABIs in
10.5% and 42.9%, respectively. Our study ﬁnding agrees with
studies by Hamed et al.17 and Tan et al.,18 which, based on
common carotid artery intima media thickness measurements,
presented observations to support the signiﬁcantly association
with acceleration of atherosclerosis in patients with epilepsy.
The main limitation of this study was that, due to ethical
guidelines, we had no patients who had never received an AED
which meant that enrollment of patients with epilepsy who had
never received an AED, the most reliable control, was simply not
an option.
There are two notable strengths of this study. It is the ﬁrst
study to focus on the effect of the CYP 2C9 polymorphism on
metabolic abnormalities and subclinical atherosclerosis in
epileptic patients taking PHT as monotherapy, and we demon-
strated that epileptic patients who had the CYP2C9 polymorphism
had lower total triglyceride, total cholesterol, LDL cholesterol, and
HDL cholesterol levels than epileptic patients who had the normal
CYP2C9 genotype. In addition, patients with the wild type also had
statistically signiﬁcantly lower ABI than patients with the CYP2C9
polymorphism. This study also excluded patients with potential
confounding factors that can affect atherosclerosis, thus our
ﬁnding that among young epileptic patients taking PHT, those
with the CYP2C9 polymorphism are at lower risk for atheroscle-
rosis than those with the wild type. These ﬁndings may have
clinical relevance to atherosclerosis in epileptic patients who are
taking PHT in populations with a high prevalence of CYP 2C9
polymorphism such as among Thais who live in Southern Thailand
compared with populations in other Asian countries or other
regions of Thailand.
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